Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

IFM Due divulges hSTING antagonists

July 22, 2021

Positive phase II data for eprenetapopt plus azacitidine in TP53 mutant MDS and AML

July 22, 2021

FDA clears IND for Viracta's all-oral combination regimen in EBV-positive solid tumors

July 22, 2021

Lantern reports promising new preclinical data for LP-184 in pancreatic cancer

July 21, 2021

Latvian Institute of Organic Synthesis discloses tubulin polymerization inhibitors

July 21, 2021

Wigen Biomedicine Technology presents GTPase KRAS mutant inhibitors

July 21, 2021

Celgene opens enrollment in phase I study of CC-90011 in metastatic CRPC

July 21, 2021

DSMB recommends continued treatment in phase II portion of OVATION 2 study with GEN-1

July 20, 2021

iOnctura initiates clinical development of next-generation autotaxin inhibitor IOA-289

July 20, 2021

Angex Pharmaceutical synthesizes new mTOR inhibitors

July 20, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...